NACI literature review on the effects of palivizumab prophylaxis on reducing the complications associated with respiratory syncytial virus in infants. : HP40-321/2022E-PDF
"The literature review examined the evidence on the effectiveness of palivizumab (PVZ) prophylaxis compared to the administration of placebo or to no prophylaxis in reducing the complications associated with RSV infection in children. The outcomes of interest included hospitalization, length of hospital stay, stay in intensive care, length of stay (LOS) in intensive care, use of oxygen therapy, length of oxygen therapy use, use of mechanical ventilation (MV), length of MV use, long-term sequelae (e.g., wheezing, asthma), and mortality"--Executive summary, page 6.
Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.914234&sl=1
| Ministère/Organisme | Public Health Agency of Canada, issuing body. |
|---|---|
| Titre | NACI literature review on the effects of palivizumab prophylaxis on reducing the complications associated with respiratory syncytial virus in infants. |
| Variante du titre | Effects of palivizumab prophylaxis on reducing complications associated with respiratory syncytial virus in infants |
| Type de publication | Monographie |
| Langue | [Anglais] |
| Autres langues publiées | [Français] |
| Format | Électronique |
| Document électronique | |
| Note(s) | Cover title. "Publication date: February 2023." At head of title: An Advisory Committee Review National Advisory Committee on Immunization (NACI). Issued also in French under title: Revue de la littérature du CCNI sur les effets de la prophylaxie par palivizumab sur la réduction des complications associées au virus respiratoire syncytial chez les nourrissons. Includes bibliographical references (pages 46-50). |
| Information sur la publication | Ottawa, Ontario : Public Health Agency of Canada = Agence de la santé publique du Canada, 2023. ©2023 |
| Description | 1 online resource (133 pages) |
| ISBN | 9780660449388 |
| Numéro de catalogue |
|
| Numéro de catalogue du ministère | 220363 |
| Descripteurs | Palivizumab -- Canada. Respiratory syncytial virus -- Canada. Infants -- Diseases -- Canada. |
Demander des formats alternatifs
Pour demander une publication dans un format alternatif, remplissez le formulaire électronique des publications du gouvernement du Canada. Utilisez le champ du formulaire «question ou commentaire» pour spécifier la publication demandée.- Date de modification :